Tarceva erlotinib regulatory update

FDA's Oncologic Drugs Advisory Committee (ODAC) will meet on Dec. 16 to discuss an sNDA from OSI for Tarceva erolitinb for first-line-maintenance treatment of advanced non-small cell lung cancer (NSCL...